Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus SORIATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus SORIATANE.
ALTRENO vs SORIATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Retinoid that binds to nuclear retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and apoptosis.
ALTRENO is not a recognized drug. No data available.
Initial: 25-50 mg orally once daily; maintenance: 25-50 mg orally once daily; not to exceed 75 mg/day.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Terminal elimination half-life of etretinate (active form) is ≈100–125 days due to storage in adipose tissue; clinically relevant for prolonged teratogenicity.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily hepatic metabolism; eliminated via feces (≈60%) and urine (≈15%) as metabolites; parent drug not excreted unchanged.
Category C
Category C
Retinoid
Retinoid